Evidence map›Paper›PMID 33550445›Full record

ReviewJournal of cancer research and clinical oncology2021

Molecular targeted treatment and drug delivery system for gastric cancer.

Lanxin Jiang, Xiaomin Gong, Wangdi Liao, Nonghua Lv, Runwei Yan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lanxin Jiang *Department of Gastroenterology, Key Laboratory of Digestive Diseases of Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Xiaomin Gong *Department of Gastroenterology, Key Laboratory of Digestive Diseases of Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Wangdi LiaoDepartment of Gastroenterology, Key Laboratory of Digestive Diseases of Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Nonghua LvDepartment of Gastroenterology, Key Laboratory of Digestive Diseases of Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Runwei YanDepartment of Gastroenterology, Key Laboratory of Digestive Diseases of Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China. Runwei_Yan0202@hotmail.com.ORCID http://orcid.org/0000-0002-1762-136X

Funding

National Natural Science Foundation of China 81960444Science and Technology Program of Health Commission of Jiangxi Province of China 20121020
6 · The paper itself

Abstract

Gastric cancer is still a major cancer worldwide. The early diagnosis rate of gastric cancer in most high incidence countries is low. At present, the overall treatment effect of gastric cancer is poor, and the median overall survival remains low. Most of the patients with gastric cancer are in an advanced stage when diagnosed, and drug treatment has become the main means. Thus, new targeted drugs and therapeutic strategies are the hope of improving the therapeutic effect of gastric cancer. In this review, we summarize the new methods and advances of targeted therapy for gastric cancer, including novel molecular targeted therapeutic agents and drug delivery systems, with a major focus on the development of drug delivery systems (drug carriers and targeting peptides). Elaborating these new methods and advances will contribute to the management of gastric cancer.

Indexed as

Drug Delivery SystemsMolecular Targeted TherapyAnimalsAntineoplastic AgentsHumansStomach NeoplasmsAntineoplastic AgentsDrug carriersDrug delivery systemsGastric cancerMolecular targeted therapyTargeted peptides

Identifiers

PMID33550445
PMCPMC11802166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.